Siamab Therapeutics Inc, 90 Bridge St, # 100, Newton, MA 02458, US

Elevian, Inc. is a biotechnology company based in Newton, MA, dedicated to developing innovative medicines that promote recovery and regeneration. Their lead program focuses on the development of a recombinant protein for the treatment of stroke, aiming to provide viable treatments for stroke patients in the days following the event, where currently there are no available options. Elevian's medicines have the potential to not only treat stroke but also prevent and address various aging-associated diseases. With stroke being a leading cause of long-term disability and the second leading cause of death globally, Elevian's research and development efforts are centered around promoting regeneration and recovery in the hours and days following a stroke. Their recombinant protein, rGDF11, has shown promising results in facilitating motor function recovery in animal models of both ischemic and hemorrhagic stroke. Additionally, rGDF11 has demonstrated potential in promoting recovery and regeneration in various preclinical models of aging-related diseases, including cardiovascular, neurological, metabolic, pulmonary, renal, inflammatory, and skeletal muscle dysfunction.Generated from the website

Hilton Hotels & Resorts

Gelmedix, Inc

Elevian, Inc

Harbour Antibodies BV